Hao Zhongping, Gu Huaiyu, Li Wen
Department of Otolaryngology, Suzhou Hospital of Anhui Medical University, Anhui, China.
Front Surg. 2022 May 27;9:855618. doi: 10.3389/fsurg.2022.855618. eCollection 2022.
We aimed to investigate the efficacy of functional endoscopic sinus surgery (FESS) combined with triamcinolone acetonide aqueous nasal spray (TAA AQ) for the treatment of chronic rhinosinusitis.
From December 2019 to June 2021, 109 patients with chronic rhinosinusitis were classified into a control group ( = 50) and an experimental group ( = 59) according to the method of treatment. Subjects in the control group were treated with FESS while those in the experimental group were treated with FESS + TAA AQ. We then compared clinical indices, total effective rate, and the clinical symptoms of patients between the two groups. The pre- and postoperative serum levels of inflammatory cytokines were also determined. Before and 12 months after surgery, we analyzed the recovery of the nasal mucosa, olfactory function, and mucociliary transport rate of each patient. Postoperative complications were observed and recorded and the quality-of-life 12 months after surgery was ascertained.
Clinical indices and total effective rate were higher in the experimental group. After treatment, the VAS score and serum levels of inflammatory cytokines in the two groups both decreased, although the experimental group had lower VAS scores and inflammatory cytokine levels. Six months after treatment, olfactory function, and the recovery of nasal mucosa were improved, MTR had increased, and the total incidence of complications had reduced in the experimental group when compared with the control group. No significant difference was found between the two groups in terms of quality-of-life ( > 0.05).
The combination of FESS and TAA AQ exerted a certain therapeutic effect on chronic rhinosinusitis.
我们旨在研究功能性鼻内镜鼻窦手术(FESS)联合曲安奈德水性鼻喷雾剂(TAA AQ)治疗慢性鼻-鼻窦炎的疗效。
2019年12月至2021年6月,109例慢性鼻-鼻窦炎患者根据治疗方法分为对照组(n = 50)和试验组(n = 59)。对照组患者接受FESS治疗,而试验组患者接受FESS + TAA AQ治疗。然后我们比较了两组患者的临床指标、总有效率和临床症状。还测定了术前和术后血清炎症细胞因子水平。在手术前和手术后12个月,我们分析了每位患者鼻黏膜的恢复情况、嗅觉功能和黏液纤毛传输速率。观察并记录术后并发症,并确定术后12个月的生活质量。
试验组的临床指标和总有效率更高。治疗后,两组的视觉模拟评分(VAS)和血清炎症细胞因子水平均下降,尽管试验组的VAS评分和炎症细胞因子水平更低。治疗6个月后,试验组的嗅觉功能、鼻黏膜恢复情况得到改善,黏液纤毛传输速率(MTR)增加,并发症总发生率降低,与对照组相比差异有统计学意义。两组在生活质量方面无显著差异(P > 0.05)。
FESS与TAA AQ联合应用对慢性鼻-鼻窦炎有一定的治疗作用。